Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Session Type:

Participation Type:

HIVR4P Home

Funding for this conference was made possible in part by 1R13AI136762-01 from the National Institute of Allergy and Infectious Diseases. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices or organizations imply endorsement by the U.S. Government.

The conference was supported by Gilead, which provided funding. Gilead has had no input into the content of the materials used at this meeting/conference.

  • Sort by:
  • Browse by:
<< first | < prev page: of 2 records per page: next > | last >>
pages: 1 2 sessions: 1 to 25 of 31
Symposium 01: We Want bNAbs: Passively Infused and Induced by Vaccines
Engineered Tandem Bispecific Neutralising Antibody for HIV-1 Prevention and Immunotherapy
Zhiwei Chen
The University of Hong Kong AIDS Institute, China
Antibody Mediated Protection (AMP): Where Are We? Which Antibodies to Use and How Will We Know If It´s Working?
Lynn Morris
National Institute for Communicable Diseases of the NHLS, South Africa
Generation of Immunogens Based on HIV-1 Envelopes From Patients With Broadly Neutralizing Responses Within the First 6 Months of Infection
Eloisa Yuste
Instituto de Salud Carlos III, Spain
HIV-1 Vaccine Design for the Elicitation of V3-glycan Broadly Neutralizing Antibodies
Kevin Saunders
Duke Human Vaccine Institute, United States
Progress in Germline-targeting Vaccine Design for HIV
William Schief
The Scripps Research Institute and IAVI, United States
from HIV Research for Prevention 2018 on 23 October 2018 15:00-16:30
Symposium 02: Early Invaders: Establishment of HIV Infection
Selection of Transmitted Founder Viruses During Sexual HIV-1 Acquisition
Manish Sagar
Boston University, United States
Identification of a New HIV Transmitting Target Cell in Human Genital Tissue
Andrew Harman
The Westmead Institute, University of Sydney, Australia
Characteristics Leading to HIV Trapping in the Female Genital Tract and Systemic Primary Infection During Transmission
Eric Arts
University of Western Ontario, Canada
Mucosal Immunology in the Context of Acute HIV Infection and HIV Remission Studies
Alexandra Schuetz
MHRP Thailand, Thailand
from HIV Research for Prevention 2018 on 23 October 2018 15:00-16:30
Symposium 03: Beyond Placebo: Designing and Implementing Next Generation HIV Prevention Trials
Regulatory Perspectives for Streamlining HIV Prevention Trials
Jeffrey Murray
FDA, United States
Novel Trial Design in the Era of Successful HIV Prevention Interventions
Deborah Donnell
Fred Hutchinson Cancer Research Center, United States
The Landscape is Changing… [It's] Quite a Complicated Issue" : Perspectives on the Standard of Prevention in South African HIV Vaccine Trials
Zaynab Essack
Human Sciences Research Council, South Africa
Strengthen Community Expertise on the Important Aspects of Clinical Trial Design
Luciana Kamel
Fiocruz, Brazil
Community Engagement in the Design and Implementation of HIV Prevention Trials: Uganda Virus Research Institute-International AIDS Vaccine Initiative
Gertrude Nanyonjo
UVRI-IAVI HIV Vaccine Program, Uganda
from HIV Research for Prevention 2018 on 23 October 2018 15:00-16:30
Symposium 04: ARVs for Prevention: Extrapolating from Data to Clinical Practice
Pharmacokinetics of PrEP Agents: Where Do Drugs Go? How Long Do They Last?
Marta Boffito
Chelsea and Westminster NHS Trust, United Kingdom
Lessons Learned from Pre-clinical Animal Models on Pharmacokinetics and Pharmacodynamics of ARVs for PrEP
Charles Dobard
Centers for Disease Control and Prevention, Division of HIV/AIDS Prevention, Laboratory Branch, United States
Understanding PrEP Effectiveness in Different Populations in the Context of Public Health Programs
Irene Mukui
National AIDS & STI Control Program, Kenya
The PrEP Paradigm for Prevention, Advocacy and Implementation in sub-Saharan Africa: Strong Starts, Short Cuts, and the Use (and Abuse?) of Data
Emily Bass
AVAC, United States
from HIV Research for Prevention 2018 on 23 October 2018 15:00-16:30
Symposium 11: ARVs for Prevention in Women of Childbearing Age
No Woman Left Behind: An Ethical Framework for Prevention Studies in Reproductive Age Women
Annie Lyerly
University of North Carolina, United States
Efavirenz and Dolutegravir: A Tale of Two ARVs
Elaine Abrams
Columbia University, United States
Studying Periconception Outcomes in Women on ARVs in Brazil
Adele Benzaken
Ministry of Health, Brazil, Brazil
Striking a Balance
Sharon Hillier
University of Pittsburgh, United States
from HIV Research for Prevention 2018 on 24 October 2018 10:30-12:00
Symposium 05: Close Encounters of the Third Kind: Innate and Adaptive Immune Responses in HIV Dissemination
Interfering with Interferons: How HIV Subverts the Interferon System to Facilitate Sexual HIV Transmission
Anthony Cunningham
The Westmead Institute, The University of Sydney, Australia
Fixed Characteristics of HLA Class I Alleles That Impact HIV Disease
Mary Carrington
Frederick National Laboratory for Cancer Research, United States
HIV Persistence and the Immune Microenvironment in Lymph Nodes Following Initiation of cART During Hyperacute HIV-1 Infection
Zaza Ndhlovu
University of KwaZulu Natal, South Africa
The First Line Against HIV/SIV: Innate Immune Effectors at the Virus-Mucosae Interface
R. Keith Reeves
Beth Israel Harvard, United States
from HIV Research for Prevention 2018 on 24 October 2018 15:00-16:30
Symposium 06: Let's Talk T Cells!
T Cell Responses in HIV-infected Children: Potential for Prevention or Cure?
Maximilian Muenchhoff
Pettenkofer-Institute, Germany
T Cells in Vaccine Trials
Wendy Burgers
Institute of Infectious Disease and Molecular Medicine, UCT, South Africa
What Defines an Effective T-cell Response to HIV?
Christian Brander
IrsiCaixa, Spain
Role of Tfh in Protective Immunity
Tony Kelleher
Kirby Institute, UNSW Sydney, Australia
Vaccine-induced Th1-biased CD4 T Cell Responses: Too Much can be Bad
Rama Amara
Emory University, United States
from HIV Research for Prevention 2018 on 24 October 2018 15:00-16:30
Symposium 07: Optimizing PrEP Delivery for PrEP Users
Integrating PrEP and Reproductive Health Services and Preparing for MPT Delivery
Renee Heffron
University of Washington, United States
New Delivery Approaches: Improving PrEP Uptake and Persistence
Nneka Nwokolo
Chelsea & Westminster Hospital, United Kingdom
PrEP Messaging: Taking “Risk” Out of the Pitch
Sarit Golub
Hunter College, United States
Mobilizing Communities Through Innovations to Improve PrEP Uptake
Nittaya Phanuphak
Thai Red Cross AIDS Research Centre, Thailand
from HIV Research for Prevention 2018 on 24 October 2018 15:00-16:30
Symposium 08: Translating Vaccine Concepts to the Clinic: What We Need to Know
Insights Into NK Cell Suppressor Activity in Secondary Lymphoid Organs Revealed by Animal Models
Michaela Muller-Trutwin
Institut Pasteur, France
Influence of Vaccine Composition on Envelope Recognition by HIV-1 Vaccine-induced Antibody-dependent Cellular-mediated Cytotoxic Responses
Guido Ferrari
Duke University Medical Center, United States
Antibody Interference and Durable Monocyte Innate Memory Decrease SIVmac251 Acquisition Risk Following Immunization with the DNA/ALVAC/gp120 Regimen
Genoveffa Franchini
National Cancer Institute, United States
Protective Gene Expression Signature of the RhCMV/SIV Vaccine: Lessons for Human Studies
Michael Gale
University of Washington, United States
Modulating Durability of HIV-1 Env Specific Humoral Immunity With 3M-052, a TLR7/8 Targeted Adjuvant
Sudhir Kasturi
Emory University, United States
from HIV Research for Prevention 2018 on 25 October 2018 13:00-14:30
Symposium 09: Choosing to Use: What People Want from HIV Prevention
Defining and Supporting Prevention Adherence
Jessica Haberer
Massachusetts General Hospital/Harvard Medical School, United States
Risk Perception and End-users' Perspective: Insights From Research of MPTs and HIV Prevention Products
Ariane van der Straten
RTI International, United States
Creating Demand for HIV Prevention Products, Programs and Services
Wanjiru Mukoma
LVCT Health, Kenya
Preference and Habits: How Do Users Decide and How Do We Find Out?
Ram Prasad
Final Mile, United States
from HIV Research for Prevention 2018 on 25 October 2018 13:00-14:30
Symposium 10: Mucosal Environment: Barriers and Facilitators of Transmission
Microbiota and HIV Transmission
Heather Jaspan
University of Cape Town/ Seattle Children's Research Institute, South Africa
High Prevalence of Bacterial STIs in HIV-positive Persons: Transmission Implications & Potential Interventions
Connie Celum
University of Washington, United States
The Rectal Mucosa in At-risk Men who Have Sex With Men: HIV Target Cells and the Inflammatory Response to Condomless Receptive Anal Intercourse
Colleen Kelley
Emory University School of Medicine, United States
How Do Different Components of the Mucosal Microenvironment Interact to Influence HIV Susceptibility?
Cara Wilson
University of Colorado, United States
from HIV Research for Prevention 2018 on 25 October 2018 13:00-14:30
Symposium 01: Vaccine-Induced Humoral Immunity
Initiation of Neutralizing Antibody B Cell Lineages by HIV Vaccine Candidates
Barton Haynes
Duke University, United States
Protection from Rectal SHIV Infection Induced by Mucosal Vaccination with a Replication-competent VSV-HIV Chimera Delivering Env Trimers
Christopher Parks
The International AIDS Vaccine Initiative, United States
Towards a Global HIV Vaccine: (Pre)-Clinical Evaluation of Prime-Boost Regimens Using Ad26 and MVA with Mosaic Antigens and Soluble Gp140 Proteins
Hanneke Schuitemaker
Janssen Vaccine and Prevention, Netherlands
Defining Correlates of Protective Humoral Immunity against HIV
Galit Alter
Ragon Institute of MGH, MIT and Harvard, United States
from HIV Research for Prevention 2016 on 18 October 2016 15:30-17:00
Symposium 02: The Role of Mucosal Barriers and Targets in HIV Acquisition
A Central Role for α4β7+ CD4+ T Cells in HIV Transmission and Pathogenesis
Claudia Cicala
National Institute of Allergy and Infectious Diseases, NIH, United States
Effects of Sex Hormones and Vaginal Microbiota on the Cervicovaginal Mucosal Barrier
Janneke van de Wijgert
University of Liverpool, United Kingdom
Tissue Compartmentalization of Human Immune Responses
Donna Farber
Columbia University Medical Center, United States
Vaginal Bacteria modulate HIV Pre-exposure Prophylaxis Efficacy in Women
Adam Burgener
Public Health Agency of Canada, Canada
from HIV Research for Prevention 2016 on 18 October 2016 15:30-17:00
Symposium 03: Choosing ARVs for Prevention: Ensuring and Measuring Effective Tissue Delivery
Location, Location, Location: Pharmacology and Tissue Delivery of ARVs
Angela Kashuba
University of North Carolina, United States
Issues with Administration Route as It Relates to Participant Preference, Dosing Strategies, and Coverage Around Times at Risk
Julie Fox
United Kingdom
Pharmacologic Approaches to Assess Adherence
Peter Anderson
University of Colorado, Denver, United States
Linking PK and PD: Choosing Drugs and Predicting Clinical Outcomes Using Data from Explant Models, Animal Models
Jim Turpin
Division of AIDS, NIAID, NIH, United States
from HIV Research for Prevention 2016 on 18 October 2016 15:30-17:00
Symposium 04: Adolescents: Bodies, Brains and Behaviors
Research Gaps in Understanding Sex Steroid Hormones and Biological and Immunological Features that May Impact Susceptibility to HIV
Sharon L. Achilles
University of Pittsburgh, United States
Promoting Resilience: Understanding Implications of Psychological Development and Decision-making
Susan Rosenthal
Columbia University Medical Center, United States
How to Talk to Me about Sex
Two Youth from Chicago - Kortez Davis and Sydney Roberson
United States
What Interventions Are Suitable for Adolescents?
Chewe Luo
UNICEF, United States
from HIV Research for Prevention 2016 on 18 October 2016 15:30-17:00
Symposium 05: Using ARVs and Antibodies for Long-Acting Prevention
One Person's Challenge Is Another Person's Opportunity: Antibody Mediated Prevention Is a Milestone Opportunity
Larry Corey
Fred Hutchinson Cancer Research Center, United States
Pipeline for Long-Acting Passive Prophylaxis: How and When Will We Choose?
Nina Russell
Bill and Melinda Gates Foundation
AAV and Other Novel Antibody Delivery Platforms
Frances Priddy
International AIDS Vaccine Initiative, United States
Engineering HIV Antibodies for Potency, Breadth and Half-life
John Mascola
National Institute of Allergy and Infectious Diseases, NIH, United States
from HIV Research for Prevention 2016 on 19 October 2016 15:30-17:00
Symposium 06: Effective Cellular Immune Reponses
Role of T Cells in Controlling HIV Infection
Andrew McMichael
University of Oxford, United Kingdom
Risk of HIV Acquisition Correlates Inversely with T Cell Polyfunctionality in Vaccine Efficacy Trials
Nicole Frahm
Fred Hutchinson Cancer Research Center, United States
Development of a Cytomegalovirus-based HIV Vaccine
Louis Picker
Oregon Health & Science University, United States
ADCC Immunity against HIV
Stephen Kent
University of Melbourne, Australia
from HIV Research for Prevention 2016 on 19 October 2016 15:30-17:00
Symposium 07: Entering the Dark Zone: Germinal Centers in Immune Response
Role of Adjuvants in Enhancing Durability of HIV Vaccine Responses by Inducing Potent Germinal Centers and Plasma Cell Responses
Sudhir Kasturi
Emory University, United States
The Many Flavors of Vaccine-Induced CD4 T Cell Responses
Hendrik Streeck
Institute for HIV Research, Germany
B Cell Follicle Sanctuary Permits Persistent Productive SIV Infection in Elite Controllers: Implications for HIV Cure
Afam Okoye
Oregon Health & Science University, United States
Selection Dynamics in the Germinal Center during Antibody Affinity Maturation
Alexander Gitlin
Rockefeller University, United States
from HIV Research for Prevention 2016 on 20 October 2016 08:30-10:00
Symposium 08: Envelope Structure and Broadly Neutralizing Antibodies
Structural Dynamics of HIV Env Glycoproteins: A Link between Structural, Functional, and Phenotypic Variation among Isolates
Kelly Lee
University of Washington, United States
The HIV Glycan Shield as a Target for Broadly Neutralizing Antibodies
Katie Doores
King's College London, United Kingdom
Immunogenicity of Multiple SOSIP Trimers in Different Animal Species
John Moore
Weill Medical College, United States
Broadly Neutralizing Antibody Lineages and Precursors
Penny Moore
University of the Witwatersrand, South Africa
from HIV Research for Prevention 2016 on 20 October 2016 08:30-10:00
Symposium 01: Overcoming Barriers to Broadly Neutralizing Antibody Induction
Prevention Strategies Based on HIV-1 Neutralizing Antibodies
John Mascola
National Institutes of Health, Bethesda, MD, United States
Broadly Neutralizing Antibody Responses in HIV-1 Infection: Insights from a Large Cohort and from Individuals
Elise Landais
IAVI Neutralizing Antibody Center at The Scripps Research Institute, La Jolla, CA, United States
HIV Envelope Interactions with the Progenitor BCRs of Narrow and Broadly Neutralizing Antibodies
Leonidas Stamatatos
Seattle Biomedical Research Institute, Seattle, WA, United States
HIV-1 Mimicry of Host Antigens: Hiding in Plain Sight to Evade Immunity
Garnett Kelsoe
Duke University, Durham, NC, United States
from HIV Research for Prevention 2014 on 28 October 2014 15:30-17:00
Symposium 02: Advances in Animal Models
Non-Human Primate Models for New Prevention Strategies of HIV Transmission
Roger Le Grand
CEA, Fontenay-aux-Roses, France
How Mice to Monkeys Inform Human B Cell Repertoire Responses
Gunilla Karlsson Hedestam
Karolinska Institutet, Stockholm, Sweden
Prevention Studies in Nonhuman Primate Models
Jeffrey Lifson
National Institutes of Health, Bethesda, MD, United States
The Role of Humanized Mice in Advancing HIV Vaccine and Eradication Studies
Todd Allen
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, United States
from HIV Research for Prevention 2014 on 28 October 2014 15:30-17:00
Symposium 03: Treatment as Prevention: The Promise and the Perils
No Time to Lose - The Importance of Early HIV Infection
Kimberly Powers
The University of North Carolina at Chapel Hill, Chapel Hill, NC, United States
A Tale of Four Treatment-as-Prevention Trials in Africa
Frank Tanser
University of KwaZulu-Natal, Mtubatuba, South Africa
Treatment as Prevention - How Can We Predict Success?
Deenan Pillay
Africa Centre for Health and Population Studies, University of KwaZulu-Natal, Mtubatuba, South Africa
TasP Promises...But What Is The Reality?
Valerie Delpech
Public Health England, London, United Kingdom
from HIV Research for Prevention 2014 on 28 October 2014 15:30-17:00
Symposium 04: Building Combination Prevention Trials
Building Combination Prevention: Trial Designs
Helen Weiss
London School of Hygiene & Tropical Medicine, London, United Kingdom
Combination Prevention: From Trials to Implementation
Sinead Delany-Moretlwe
University of the Witwatersrand, Johannesburg, South Africa
The Role of Mathematical Modeling to Design, Conduct, Interpret and Replicate HIV Prevention Trials
Marie-Claude Boily
Imperial College London, London, United Kingdom
Scalable Adherence Interventions
Terrence Blaschke
Bill and Melinda Gates Foundation, Seattle, WA, United States
from HIV Research for Prevention 2014 on 28 October 2014 15:30-17:00
Symposium 05: The Role of Structure Based Design in Vaccine Development and Immunoprophylaxis
Structure-Based Design of Improved Antibodies for HIV-1 Treatment or Prevention
Pamela Bjorkman
California Institute of Technology, Pasadena, CA, United States
The Stucture of the Glycan Shield of HIV
Max Crispin
University of Oxford, Oxford, United Kingdom
Structure-Based Stabilization of the Prefusion Closed HIV-1 Env Trimer
Peter Kwong
National Institutes of Health, Bethesda, MD, United States
Reductionist Vaccine Design to Induce Broadly Neutralizing Antibodies against HIV
William Schief
The Scripps Research Institute, La Jolla, CA, United States
from HIV Research for Prevention 2014 on 29 October 2014 15:30-17:00
Symposium 06: Harnessing Antibody Effector Functions
Evaluating HIV-1 Vaccine Induced Antibody Effector Function to Advance Vaccine Candidates
Georgia Tomaras
Duke University, Durham, NC, United States
A Systems Serology Approach to Vaccination
Margie Ackerman
Dartmouth College, Hanover, NH, United States
Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques
Sampa Santra
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States
Combating Cell-Cell Transmission of HIV with Antibodies - Slaying the Trojan Horse?
Stephen Kent
University of Melbourne, Melbourne, Australia
from HIV Research for Prevention 2014 on 29 October 2014 15:30-17:00
<< first | < prev page: of 2 records per page: next > | last >>
pages: 1 2 sessions: 1 to 25 of 31